Organigram Global (NASDAQ:OGI) Posts Earnings Results, Hits Estimates

Organigram Global (NASDAQ:OGI) announced its quarterly earnings data on Tuesday. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01), Zacks reports. Organigram Global had a net margin of 6.03% and a negative return on equity of 15.41%.

Here are the key takeaways from Organigram Global’s conference call:

• OrganiGram reported a challenging Q2, with net revenue of CAD 59.8 million, down about 9% year over year, as execution issues in vapes and infused pre-rolls weighed on results.
• Adjusted gross margin fell to 31% and adjusted EBITDA dropped to CAD 0.9 million, reflecting weaker mix, higher returns, and lower recreational revenue. Net loss also included a CAD 5.8 million impairment tied to the company’s U.S. hemp-derived products business.
• Management said the main operational problems in pre-rolls and vapes have been identified and remediated, and they are already seeing improving quality and competitiveness. They expect recovery to continue in Q3 and Q4, alongside seasonal tailwinds.
• The company emphasized strong underlying performance in other categories, including flower share gains, continued strength in edibles, beverages, and concentrates, and a record quarterly harvest of over 32,000 kilograms. OrganiGram also said its cultivation yields and genetics work are lowering costs and improving efficiency.
• Management expects the Sanity Group acquisition to drive a meaningful step-up in the second half of fiscal 2026, supporting international growth, especially in Germany and other European markets. Reflecting this, OrganiGram raised guidance to net revenue above CAD 350 million, with adjusted EBITDA and adjusted gross margin above FY2025 levels and free cash flow near breakeven.

Organigram Global Stock Performance

Shares of OGI stock traded down $0.19 during trading hours on Tuesday, hitting $1.13. 2,120,785 shares of the company were exchanged, compared to its average volume of 746,616. Organigram Global has a one year low of $1.10 and a one year high of $2.24. The business’s 50-day simple moving average is $1.41 and its two-hundred day simple moving average is $1.54. The stock has a market capitalization of $158.37 million, a price-to-earnings ratio of 8.04 and a beta of 1.50.

Institutional Trading of Organigram Global

Several large investors have recently added to or reduced their stakes in OGI. Virtu Financial LLC acquired a new position in shares of Organigram Global during the fourth quarter worth approximately $188,000. Millennium Management LLC bought a new position in Organigram Global during the fourth quarter worth about $1,260,000. Lazard Asset Management LLC bought a new position in shares of Organigram Global in the fourth quarter worth $280,000. Walleye Capital LLC bought a new position in shares of Organigram Global in the fourth quarter worth about $25,000. Finally, HRT Financial LP acquired a new position in Organigram Global during the fourth quarter worth $52,000. 34.63% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Organigram Global from a “hold” rating to a “sell” rating in a research note on Saturday. Canaccord Genuity Group assumed coverage on shares of Organigram Global in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Finally, ATB Cormark Capital Markets lowered Organigram Global from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, February 11th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold”.

About Organigram Global

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.